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ABSTRACT
Initial antibiotic therapy for diabetic foot infections is usually empirical. Several principles may help to
avoid selecting either an unnecessarily broad or inappropriately narrow regimen. First, clinically severe
infections require broad-spectrum therapy, while less severe infections may not. Second, aerobic Gram-
positive cocci, particularly Staphylococcus aureus (including methicillin-resistant S. aureus (MRSA) for
patients at high-risk) should always be covered. Third, therapy should also be targeted at aerobic Gram-
negative pathogens if the infection is chronic or has failed to respond to previous antibiotic therapy.
Fourth, anti-anaerobe agents should be considered for necrotic or gangrenous infections on an ischaemic
limb. Parenteral therapy is needed for severe infections, but oral therapy is adequate for most mild or
moderate infections.
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Foot infections are common in individuals with
diabetes. Among the decisions that the clinician
treating such a patient must make is to select the
most appropriate antibiotic regimen, usually in
the face of inadequate microbiological informa-
tion. If too narrow a spectrum is chosen, there is a
risk of missing a pathogen in these often polymi-
crobial infections, potentially leading to a poor
clinical outcome. Opting for unnecessarily broad-
spectrum therapy contributes to the growing
problem of antibiotic resistance, and potentially
increases the risk of drug toxicity and treatment
expense. Considering that initial treatment is
empirical in about two-thirds of cases, how is a
responsible clinician to decide?
Some basic principles can provide guidance.
First, criteria established by the Infectious Dis-
eases Society of America [1] or the International
Working Group on the Diabetic Foot [2] should be
used to determine the severity of the infection.
Broad-spectrum therapy is usually needed only
for patients with severe infections; these require
an adequate antibiotic regimen until the results of
culture are available. Mild, and most moderate,
infections can often be treated with an agent with
a more narrow spectrum of activity. Even if some
organisms isolated from an infection are found to
be resistant to the selected regimen, most patients
with non-severe infections will improve (or at
least stabilise) if they receive proper supportive
care, debridement, pressure off-loading and
wound care.
Second, therapy should virtually always in-
clude coverage for aerobic Gram-positive cocci,
especially Staphylococcus aureus, which is both the
most frequent and virulent pathogen isolated.
Whether or not empirical coverage for methicillin-
resistant S. aureus (MRSA) should be provided is
a growing concern worldwide [3,4]. This decision
depends largely on the overall local prevalence of
MRSA, and the presence or absence of risk-factors
for MRSA infection, e.g., recent hospitalisation or
residence in a healthcare facility, recent antibiotic
therapy or a requirement for renal dialysis.
Agents that cover S. aureus will usually cover
the b-haemolytic streptococci that are also relat-
ively frequent pathogens. While enterococci are
often isolated from diabetic foot infections, they
are rarely primary pathogens, and are often
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simply colonisers [5] that do not usually require
speciﬁcally targeted therapy. One exception may
be patients who are failing to respond to treat-
ment with a cephalosporin, as these agents can
predispose to infection with Enterococcus spp.
Third, the time to target aerobic Gram-negative
bacilli must be considered. These microorganisms
are isolated in up to two-thirds of infections, but
usually from patients with a chronic infection
who have recently received antibiotic therapy.
Various Enterobacteriaceae are the most frequent
Gram-negative isolates, and these are covered by
most commonly used advanced broad-spectrum
agents. The main issue with Gram-negative cov-
erage is to decide when to speciﬁcally target
Pseudomonas aeruginosa. This organism is usually
found in water, and is thus most often isolated
from patients who have been receiving some form
of hydrotherapy. Pseudomonas is among the more
commonly isolated organisms in some popula-
tions [6,7], but is usually found as part of a
polymicrobial infection [5,8]. In general, antibiotic
therapy does not need to be directed at Pseudo-
monas isolates unless they are the predominant
pathogens from a deep tissue specimen. Coverage
of all Gram-negative isolates, especially extended-
spectrum b-lactamase producers and resistant
Pseudomonas spp., would require a broader-spec-
trum regimen than is usually necessary.
Fourth, the role of obligate anaerobic bacteria
should be considered. Studies that have properly
obtained and processed specimens to allow isola-
tion of anaerobes show that they are present in a
substantial minority of cases [9–11]. However, as
with Pseudomonas, they are usually isolated in a
mixed infection with aerobes, rather than as a sole
pathogen [5]. Anaerobes are isolated more often
from patients with limb ischaemia and conse-
quent necrosis or gangrene. A clinical clue to the
presence of anaerobes is the feculent odour that
they produce. Debriding necrotic material, and
thereby removing many of the anaerobes and
exposing those remaining to air, may be all that is
needed to treat these potential pathogens. Thus,
an antibiotic regimen aimed speciﬁcally at anaer-
obes is required only when there is strong clinical
evidence of anaerobic infection, i.e., the classic
‘fetid foot’ [12].
Finally, having considered the likely aetiologi-
cal agents and appropriate antibiotic choices, the
route of therapy must also be decided. Severe
infections require parenteral therapy to achieve
reliable blood levels quickly. The advent of highly
bioavailable oral antimicrobial agents, e.g., ﬂuoro-
quinolones and linezolid, has made oral therapy
more acceptable. Several studies of the treatment
of diabetic foot infections have revealed excellent
outcomes with oral antibiotics alone [13,14]. The
important issue is whether or not an adequate
level of antibiotic reaches the infected tissue, not
how it arrives there. Thus, many patients can be
treated with a quick switch to oral agents when
they clinically improve, or even with initial oral
therapy. For some mildly infected and superﬁcial
wounds, topical therapy may be another option
[15–17].
In conclusion, as shown in Table 1, relatively
narrow-spectrum therapy directed against aerobic
Gram-positive cocci, e.g., a semi-synthetic peni-
cillin or ﬁrst-generation cephalosporin, may be
adequate for many acute infections in patients
who have not recently been treated with an
Table 1. Guide to selecting an empirical antibiotic regimen for a diabetic foot infection
Type of infection Likely pathogen(s) Class of antibiotic(s)
Acute, antibiotic-naive;
low-risk MRSA
Aerobic GPC Penicillins; ﬁrst-generation cephalosporins
Healthcare-associated; MRSA Co-trimoxazole; doxycycline;
high local rates of MRSA clindamycin; glycopeptide;
linezolid; daptomycin
Chronic, previous
antibiotic treatment
GPC + GNR
± anaerobes
b-Lactam, b-lactamase inhibitor;
second- or third-generation
cephalosporin; group 1 carbapenem; FQ
Necrotic, gangrenous
ischaemic limb;
foul odour
GPC + GNB
obligate anaerobes
Clindamycin (± FQ);
metronidazole (+ FQ);
b-lactam, b-lactamase inhibitor;
carbapenem
Hydrotherapy;
green–blue-coloured
drainage
Pseudomonas
aeruginosa
Anti-pseudomonal FQ,
penicillin or cephalosporin
GPC, Gram-positive cocci; GNB, Gram-negative bacilli; FQ, ﬂuoroquinolone; MRSA, methicillin-resistant Staphylococcus aureus.
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antibiotic. Where MRSA is a concern, community-
acquired infections may be treated effectively
with co-trimoxazole, doxycycline or clindamycin;
hospital-acquired strains often require a glyco-
peptide, linezolid or daptomycin. As infections
become chronic, and particularly if they fail to
respond to antibiotic therapy, they tend to
become polymicrobial, with the addition of
Gram-negative bacilli. In these instances, broad-
er-spectrum treatment, accomplished either with
appropriate single or combination agents, is
judicious. Necrotic or gangrenous wounds, espe-
cially in a patient with poor arterial ﬂow, are often
infected with anaerobes that may act synergically
with the aerobes, and thus require anti-anaerobic
therapy, e.g., with clindamycin, metronidazole or
a broader-spectrum agent with good anaerobic
coverage.
Other clues may help to predict the probable
pathogen(s) in a diabetic foot infection. Any
available previous wound culture results should
be checked, and the possibility of recent antibiotic
therapy or hospitalisations that could increase the
likelihood of drug-resistant bacteria should be
investigated [18]. Gram’s-stained smears of
wound specimens should be reviewed [19,20].
While there are few published data concerning
patients with diabetic foot infections, the Gram’s
stain results should inform the clinician about the
morphological and tinctorial properties of iso-
lates. Speciﬁcally, when the smear shows a poly-
microbial infection, broader coverage is
appropriate; otherwise, a narrower spectrum of
antimicrobial coverage may sufﬁce. Using the
principles cited above, clinicians can offer a
patient with a diabetic foot infection the ‘just
right’ choice of empirical antibiotic therapy.
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